Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumor burden (HTB) indolent non-Hodgkin lymphoma (iNHL): A multicenter phase II study.
Andrew M. Evens
Consultant or Advisory Role - Millennium
Research Funding - Millennium
Mitchell Reed Smith
Research Funding - Millennium
Izidore S. Lossos
Research Funding - Millennium
Michael Mark Millenson
No relevant relationships to disclose
Jane N. Winter
Research Funding - Millennium
Steven T. Rosen
No relevant relationships to disclose
Leo I. Gordon
Research Funding - Millennium